Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation

Annals of the New York Academy of Sciences

Volumn 1243, Issue 1, 2011, Pages 54-68

  Gallagher, Emily Jane ^a   Leroith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diabetes; Insulin resistance; Metformin

Indexed keywords

FAS LIGAND; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GROWTH HORMONE RECEPTOR; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN C RECEPTOR; SULFONYLUREA; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CALORIC RESTRICTION; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME MUTATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN BINDING; INSULIN RESISTANCE; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONCOGENE C MYC; ONCOGENE RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 84255178432     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06285.x     Document Type: Article

References (138)

1. Maynard, G. 1910. A statistical study in cancer death-rates. Biometrika 7: 276-304.
2. Pearson, K., A. Lee & E.M. Elderton. 1910. On the correlation of death-rates. J. R. Stat. Soc. 73: 534-539.
3. Srokowski, T.P., S. Fang, G.N. Hortobagyi & S.H. Giordano. 2009. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J. Clin. Oncol. 27: 2170-2176.
4. Barone, B.B., H.C. Yeh, C.F. Snyder, et al. 2008. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300: 2754-2764.
5. Coughlin, S.S., E.E. Calle, L.R. Teras, et al. 2004. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am. J. Epidemiol. 159: 1160-1167.
6. Everhart, J. & D. Wright. 1995. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273: 1605-1609.
7. Huxley, R., A. Ansary-Moghaddam, A. Berrington de Gonzalez, et al. 2005. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92: 2076-2083.
8. Friberg, E., N. Orsini, C.S. Mantzoros & A. Wolk. 2007. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50: 1365-1374.
9. El-Serag, H.B., H. Hampel & F. Javadi. 2006. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4: 369-380.
10. Larsson, S.C., N. Orsini, K. Brismar & A. Wolk. 2006. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49: 2819-2823.
11. MacKenzie, T., M.S. Zens, A. Ferrara, et al. 2010. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 117: 1552-1556.
12. Larsson, S.C. & A. Wolk. 2011. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54: 1013-1018.
13. Larsson, S.C., N. Orsini & A. Wolk. 2005. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst. 97: 1679-1687.
14. Larsson, S.C., C.S. Mantzoros & A. Wolk. 2007. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 121: 856-862.
15. Peairs, K.S., B.B. Barone, C.F. Snyder, et al. 2011. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J. Clin. Oncol. 29: 40-46.
16. Kasper, J.S. & E. Giovannucci. 2006. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15: 2056-2062.
17. Bonovas, S., K. Filioussi & A. Tsantes. 2004. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47: 1071-1078.
18. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Centers for Disease Control and Prevention; 2011.
19. Giovannucci, E., D.M. Harlan, M.C. Archer, et al. 2010. Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685.
20. Martin, B.C., J.H. Warram, A.S. Krolewski, et al. 1992. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340: 925-929.
21. American Diabetes Association. 2011. Standards of medical care in diabetes-2011. Diabetes Care 34(Suppl 1): S11-S61.
22. West, K.M. & J.M. Kalbfleisch. 1971. Influence of nutritional factors on prevalence of diabetes. Diabetes 20: 99-108.
23. Calle E.E., C. Rodriguez, K. Walker-Thurmond & M.J. Thun. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348: 1625-1638.
24. Poretsky, L. 2010. Chapter 36 in Principles of Diabetes. 2nd ed. Springer. New York.
25. LeRoith, D. 2011. Chapter 3 in Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics. Springer. New York.
26. Bowker, S.L., S.R. Majumdar, P. Veugelers & J.A. Johnson. 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
27. Colhoun, H.M. 2009. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755-1765.
28. Currie, C.J., C.D. Poole & E.A. Gale. 2009. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
29. Libby, G., L.A. Donnelly, P.T. Donnan, et al. 2009. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.
30. Bodmer, M., C. Meier, S. Krahenbuhl, et al. 2010. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308.
31. Levine, A.J. & A.M. Puzio-Kuter. 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344.
32. Peterson, C.W. & D.E. Ayer. 2011. An extended Myc network contributes to glucose homeostasis in cancer and diabetes. Front. Biosci. 17: 2206-2223.
33. Paz-Filho, G., E.L. Lim, M.L. Wong & J. Licinio. 2011. Associations between adipokines and obesity-related cancer. Front. Biosci. 16: 1634-1650.
34. DeBerardinis, R.J. & T. Cheng. 2010. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324.
35. Tran, T.T., A. Medline & W.R. Bruce. 1996. Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev. 5: 1013-1015.
36. Tran, T.T., D. Naigamwalla, A.I. Oprescu, et al. 2006. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 147: 1830-1837.
37. Gunter, M.J., D.R. Hoover, H. Yu, et al. 2009. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 101: 48-60.
38. Goodwin, P.J., M. Ennis, K.I. Pritchard, et al. 2002. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20: 42-51.
39. Ma, J., E. Giovannucci, M. Pollak, et al. 2004. A prospective study of plasma C-peptide and colorectal cancer risk in men. J. Natl. Cancer Inst. 96: 546-553.
40. Wei, E.K., J. Ma, M.N. Pollak, et al. 2005. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol. Biomarkers Prev. 14: 850-855.
41. Albanes, D., S.J. Weinstein, M.E. Wright, et al. 2009. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J. Natl. Cancer Inst. 101: 1272-1279.
42. Eliassen, A.H., S.S. Tworoger, C.S. Mantzoros, et al. 2007. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol. Biomarkers Prev. 16: 161-164.
43. Novosyadlyy, R., D.E. Lann, A. Vijayakumar, et al. 2010. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 70: 741-751.
44. Baxter, RC., A.S. Brown & J.R. Turtle. 1980. Association between serum insulin, serum somatomedin and liver receptors for human growth hormone in streptozotocin diabetes. Horm. Metab. Res. 12: 377-381.
45. Major, J.M., G.A. Laughlin, D. Kritz-Silverstein, et al. 2010. Insulin-like growth factor-I and cancer mortality in older men. J. Clin. Endocrinol. Metab. 95: 1054-1059.
46. Chen, W., S. Wang, T. Tian, et al. 2009. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur. J. Hum. Genet. 17: 1668-1675.
47. Rinaldi, S., R. Cleveland, T. Norat, et al. 2010. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int. J. Cancer 126: 1702-1715.
48. Roddam, A.W., N.E Allen, P. Appleby, et al. 2008. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 149: 461-471, W83-W88.
49. Renehan, A.G., M. Zwahlen, C. Minder, et al. 2004. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353.
50. Wu, Y., S. Yakar, L. Zhao, et al. 2002. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 62: 1030-1035.
51. Dunn, S.E., F.W. Kari, J. French, et al. 1997. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 57: 4667-4672.
52. Papa, V., V. Pezzino, A. Costantino, et al. 1990. Elevated insulin receptor content in human breast cancer. J. Clin. Invest. 86: 1503-1510.
53. Mathieu, M.C., G.M. Clark, D.C. Allred, et al. 1997. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc. Assoc. Am. Physicians 109: 565-571.
54. Mulligan, A.M., F.P. O'Malley, M. Ennis, et al. 2007. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res. Treat. 106: 39-47.
55. Spector, S.A., E.T. Olson, A.A. Gumbs, et al. 1999. Human insulin receptor and insulin signaling proteins in hepatic disease. J. Surg. Res. 83: 32-35.
56. Cox, M.E., M.E. Gleave, M. Zakikhani, et al. 2009. Insulin receptor expression by human prostate cancers. Prostate 69: 33-40.
57. Saiya-Cork, K., R. Collins, B. Parkin, et al. 2011. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin. Cancer Res. 17: 2679-2692.
58. Dinchuk, J.E., C. Cao, F. Huang, et al. 2010. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. Endocrinology 151: 4123-4132.
59. Ulanet, D.B., D.L. Ludwig, C.R. Kahn & D. Hanahan. 2010. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Natl. Acad. Sci. USA 107: 10791-10798.
60. Zhang, H., A.M. Pelzer, D.T. Kiang & D. Yee. 2007. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 67: 391-397.
61. Buck, E., P.C. Gokhale, S. Koujak, et al. 2010. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 9: 2652-2664.
62. Levine, A.J., Z. Feng, T.W. Mak, et al. 2006. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 20: 267-275.
63. Gwinn, D.M., D.B. Shackelford, D.F. Egan, et al. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30: 214-226.
64. Fu, Z. & D.J. Tindall. 2008. FOXOs, cancer and regulation of apoptosis. Oncogene 27: 2312-2319.
65. Smolewski, P. 2006. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17: 487-494.
66. Sen, P., S. Mukherjee, D. Ray & S. Raha. 2003. Involvement of the Akt/PKB signaling pathway with disease processes. Mol. Cell Biochem. 253: 241-246.
67. Laporte, D., A. Lebaudy, A. Sahin, et al. 2011. Metabolic status rather than cell cycle signals control quiescence entry and exit. J. Cell Biol. 192: 949-957.
68. Warburg, O. 1956. On the origin of cancer cells. Science 123: 309-314.
69. Hsu, P.P. & D.M. Sabatini. 2008. Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
70. Johnson, J.A. & S.L. Bowker. 2011. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54: 25-31.
71. Stattin, P., O. Bjor, P. Ferrari, et al. 2007. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30: 561-567.
72. Yang, X., G.T. Ko, W.Y. So, et al. 2010. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 59: 1254-1260.
73. Okumura, M., M. Yamamoto, H. Sakuma, et al. 2002. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim. Biophys. Acta 1592: 107-1016.
74. Liu, H., Q. Ma & J. Li. 2011. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol. Cell Biochem. 347: 95-101.
75. Nunez, N.P., W.J. Oh, J. Rozenberg, et al. 2006. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res. 66: 5469-5476.
76. Heuson, J.C. & N. Legros. 1972. Influence of insulin deprivation on growth of the 7, 12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 32: 226-232.
77. Frezza, C. & E. Gottlieb. 2009. Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 19: 4-11.
78. Macheda, M.L., S. Rogers & J.D. Best. 2005. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 202: 654-662.
79. Haber, R.S., K.R. Weiser, A. Pritsker, et al. 1997. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 7: 363-367.
80. Kurata, T., T. Oguri, T. Isobe, et al. 1999. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn. J. Cancer Res. 90: 1238-1243.
81. Yamamoto, T., Y. Seino, H. Fukumoto, et al. 1990. Over-expression of facilitative glucose transporter genes in human cancer. Biochem. Biophys. Res. Commun. 170: 223-230.
82. Younes, M., R.W. Brown, D.R. Mody, et al. 1995. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 15: 2895-2898.
83. Baer, S.C., L. Casaubon, M. Younes. 1997. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J. Am. Acad. Dermatol. 37: 575-577.
84. Nagase, Y., K. Takata, N. Moriyama, et al. 1995. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J. Urol. 153: 798-801.
85. Nagamatsu, S., H. Sawa, A. Wakizaka & T. Hoshino. 1993. Expression of facilitative glucose transporter isoforms in human brain tumors. J. Neurochem. 61: 2048-2053.
86. Noguchi, Y., S. Sato, D. Marat, et al. 1999. Glucose uptake in the human gastric cancer cell line, MKN28, is increased by insulin stimulation. Cancer Lett. 140: 69-74.
87. Armoni, M., M.J. Quon, G. Maor, et al. 2002. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro. J. Clin. Endocrinol. Metab. 87: 5312-5324.
88. Ito, T., Y. Noguchi, S. Satoh, et al. 1998. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod. Pathol. 11: 437-443.
89. Schwartzenberg-Bar-Yoseph, F., M. Armoni & E. Karnieli. 2004. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64: 2627-2633.
90. Cifuentes, M., M.A. Garcia, P.M. Arrabal, et al. 2011. Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells. J. Cell Physiol. 226: 1425-1432.
91. Ding, X.Z., D.M. Fehsenfeld, L.O. Murphy, et al. 2000. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 21: 310-320.
92. Bensaad, K., A. Tsuruta, M.A. Selak, et al. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
93. Kawauchi, K., K. Araki, K. Tobiume & N. Tanaka. 2008. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 10: 611-618.
94. Jiang, P., W. Du, X. Wang, et al. 2011. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13: 310-316.
95. Sun, Q., X. Chen, J. Ma, et al. 2011. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 108: 4129-4134.
96. Walenta, S., M. Wetterling, M. Lehrke, et al. 2000. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60: 916-921.
97. Shim, H., C. Dolde, B.C. Lewis, et al. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 94: 6658-6663.
98. Dang, C.V., J.W. Kim, P. Gao & J. Yustein. 2008. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 8: 51-56.
99. Martinez-Outschoorn, U.E., M. Prisco, A. Ertel, et al. 2011. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 10: 1271-1286.
100. Huang, Z., S.E. Hankinson, G.A. Colditz, et al. 1997. Dual effects of weight and weight gain on breast cancer risk. JAMA 278: 1407-1411.
101. Pugeat, M, N. Nader, K. Hogeveen, et al. 2010. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol. Cell Endocrinol. 316: 53-59.
102. Eertmans, F, W. Dhooge, O. De Wever, et al. 2007. Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line. J. Cell Physiol. 212: 583-590.
103. Richardson, A.E., N. Hamilton, W. Davis, et al. 2011. Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-alpha and -beta via the IGF-1 and the insulin receptors in breast cancer cells. Growth Factors 29: 82-93.
104. Rosato, V., C. Bosetti, R. Bosetti, et al. 2011. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann. Oncol. [Epub ahead of Print]. doi:.
105. Rosato, V., A. Zucchetto, C. Bosetti, et al. 2011. Metabolic syndrome and endometrial cancer risk. Ann. Oncol. 22: 884-889.
106. Tannenbaum, A. & H. Silverstone. 1949. The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice. Cancer Res. 9: 724-727.
107. Colman, R.J., R.M. Anderson, S.C. Johnson, et al. 2009. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325: 201-204.
108. Moore, T., S. Carbajal, L. Beltran, et al. 2008. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res. 68: 3680-3688.
109. Hursting, S.D., S.M. Smith, L.M. Lashinger, et al. 2010. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 31: 83-89.
110. Yang, X., W.Y. So, R.C. Ma, et al. 2011. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 34: 375-380.
111. Donadon, V., M. Balbi, F. Valent & A. Avogaro. 2010. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J. Gastroenterol. 16: 3025-3032.
112. Buchs, A.E. & B.G. Silverman. 2011. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism. 60: 1379-1385.
113. Decensi, A., M. Puntoni, P. Goodwin, et al. 2010. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila) 3: 1451-1461.
114. Evans, J.M., L.A. Donnelly, A.M. Emslie-Smith, et al. 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
115. Landman, G.W., N. Kleefstra, K.J. van Hateren, et al. 2010. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326.
116. Monami, M., C. Colombi, D. Balzi, et al. 2011. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 34: 129-131.
117. Jiralerspong, S., S.L. Palla, S.H. Giordano, et al. 2009. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27: 3297-3302.
118. He, X.X., S.M. Tu, M.H. Lee & S.C. Yeung. 2011. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann. Oncol. [Epub ahead of Print]. doi:.
119. Baur, D.M., J. Klotsche, O.P. Hamnvik, et al. 2010. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 60: 1363-1371.
120. Hadad, S., T. Iwamoto, L. Jordan, et al. 2011. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 128: 783-794.
121. El-Mir, M.Y., V. Nogueira, E. Fontaine, et al. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275: 223-228.
122. Zhuang, Y. & W.K. Miskimins. 2008. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 3: 18-28.
123. Zakikhani, M., R. Dowling, I.G. Fantus, et al. 2006. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66: 10269-10273.
124. Gotlieb, W.H., J. Saumet, M.C. Beauchamp, et al. 2008. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110: 246-250.
125. Ben Sahra, I., C. Regazzetti, G. Robert, et al. 2011. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71: 4366-4372.
126. Ben Sahra, I., K. Laurent, A. Loubat, et al. 2008. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586.
127. Foretz, M., S. Hebrard, J. Leclerc, et al. 2010. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120: 2355-2369.
128. Ota, S., K. Horigome, T. Ishii, et al. Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism. Biochem. Biophys. Res. Commun. 388: 311-316.
129. Caton, P.W., N.K. Nayuni, J. Kieswich, et al. 2010. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol. 205: 97-106.
130. Algire, C., L. Amrein, M. Zakikhani, et al. 2010. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr. Relat. Cancer 17: 351-360.
131. Goodwin, P.J., K.I. Pritchard, M. Ennis, et al. 2008. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8: 501-505.
132. Zakikhani, M., M.J. Blouin, E. Piura & M.N. Pollak. 2010. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat. 123: 271-279.
133. Kisfalvi, K., G. Eibl, J. Sinnett-Smith & E. Rozengurt. 2009. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 69: 6539-6545.
134. Brown, K.A., N.I. Hunger, M. Docanto & E.R. Simpson. 2010. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res. Treat. 123: 591-596.
135. Hirsch, H.A., D. Iliopoulos, P.N. Tsichlis & K. Struhl. 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69: 7507-7511.
136. Iliopoulos, D., H.A. Hirsch & K. Struhl. 2011. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71: 3196-3201.
137. Vazquez-Martin, A., C. Oliveras-Ferraros, S. Cufi, et al. 2010. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 9: 3807-3814.
138. Vazquez-Martin, A., C. Oliveras-Ferraros, S. Del Barco, et al. 2011. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. 126: 355-364.